Shift Labs, Inc., a Seattle-based company building affordable, simple gravity IV infusion devices for alternate site care and emerging markets, announced today that it has received CE Mark approval for the DripAssist Infusion Rate Monitor” Shift Labs (2017).
“We look forward to introducing the DripAssist Infusion Rate Monitor to European Union member countries and Canada,” said Shift Labs CEO Beth Kolko. “We’re especially excited to provide our cost-effective, easy-to-use gravity IV monitoring solution to these forward-thinking markets that want to provide the most affordable and efficient care for patients.”
ReTweet if useful… Shift Labs’ DripAssist infusion rate monitor receives CE mark approval for Europe https://ctt.ec/tdTev+ @ivteam #ivteam
The award-winning DripAssist is a simple, compact device that clips to any IV drip to monitor the rate at which medication or fluids are delivered. It is the only precision instrument that provides consistent monitoring for gravity IV infusion, bringing two best-in-class benefits to any clinical setting: 1) accurate medication dosing for safer care, and 2) measurable clinical time and cost savings. Designed to provide quality care in any healthcare environment, DripAssist’s core technology provides a versatile, low-cost mechanism to enable widespread IV infusion monitoring.Full Press Release
Thank you to our partners for supporting IVTEAM